Search

Develop the analytical skills that are in high demand in businesses today with Camm/Cochran/Fry/Ohlmann's best-selling BUSINESS ANALYTICS, CENGAGE INTERNATIONAL EDITION 5E. You master the full range of analytics as you strengthen descriptive, predictive and prescriptive analytic skills. Real examples and memorable visuals clearly illustrate data and results. Step-by-step instructions guide you through using Excel, Tableau, R or the Python-based Orange data mining software to perform advanced analytics. Practical, relevant problems at all levels of difficulty let you apply what you've learned. Updates throughout this edition address topics beyond traditional quantitative concepts, such as data wrangling, data visualization and data mining, which are increasingly important in today's business environment. MindTap and WebAssign online learning platforms are also available with an interactive eBook, algorithmic practice problems and Exploring Analytics visualizations to strengthen your understanding of key concepts.

Develop the analytical skills that are in high demand in businesses today with Camm/Cochran/Fry/Ohlmann's best-selling BUSINESS ANALYTICS, 5E. You master the full range of analytics as you strengthen descriptive, predictive and prescriptive analytic skills. Real examples and memorable visuals clearly illustrate data and results. Step-by-step instructions guide you through using Excel, Tableau, R or the Python-based Orange data mining software to perform advanced analytics. Practical, relevant problems at all levels of difficulty let you apply what you've learned. Updates throughout this edition address topics beyond traditional quantitative concepts, such as data wrangling, data visualization and data mining, which are increasingly important in today's business environment. MindTap and WebAssign online learning platforms are also available with an interactive eBook, algorithmic practice problems and Exploring Analytics visualizations to strengthen your understanding of key concepts.

Introduction to Management Science ISE

Develop the analytical skills that are in high demand in businesses today with Camm/Cochran/Fry/Ohlmann's best-selling BUSINESS ANALYTICS, 4E. You master the full range of analytics as you strengthen descriptive, predictive and prescriptive analytic skills. Real examples and memorable visuals illustrate data and results for each topic. Step-by-step instructions guide you through using Microsoft® Excel, Tableau, R, and JMP Pro software to perform even advanced analytics concepts. Practical, relevant problems at all levels of difficulty further help you apply what you've learned. This edition assists you in becoming proficient in topics beyond the traditional quantitative concepts, such as data visualization and data mining, which are increasingly important in today's analytical problem solving. MindTap digital learning resources with an interactive eBook, algorithmic practice problems with solutions and Exploring Analytics visualizations strengthen your understanding of key concepts.

The impact of globalization on world health has been extremely positive. However, the increased connectivity enabled by globalization also makes the health and well being of citizens around the world more important than ever. Global pandemics, natural disasters, air pollution, medical care access, healthy food chains, immunization education and availability, and economic disparity all factor into creating a healthy population. Why is global health so important, and what stands in the way of achieving it? Through viewpoints written by experts in the field, this volume highlights important issues in global health around the world.

Develop a strong conceptual understanding of statistics and its importance in business today. MODERN BUSINESS STATISTICS WITH MICROSOFT® EXCEL®, 7E balances real-world applications with an integrated focus on the latest version of Microsoft® Excel®. This best-selling, comprehensive edition clearly develops each statistical technique in an application setting. You master statistical methodology with an easy-to-follow presentation of a statistical procedure followed by a discussion of how to use Excel® to perform the procedure. Step-by-step instructions and screen images reinforce understanding. More than 160 new business examples, proven methods, and application exercises show how statistics provide insights into business decisions and problems. A problem-scenario approach emphasizes how to apply statistical methods to practical business situations. New case problems let you check your understanding, while MindTap digital resources help you master Excel®, Excel Online, and R.

The Sixth edition of Introduction to Management Science focuses on business situations, including prominent non-mathematical issues, the use spreadsheets, and involves model formulation and assessment more than model structuring. The text has three key elements: modeling, case studies, and spreadsheets. In addition to examples, nearly every chapter includes one or two case studies patterned after actual applications to convey the whole process of applying management science.

Microbial threats, including endemic and emerging infectious diseases and antimicrobial resistance, can cause not only substantial health consequences but also enormous disruption to economic activity worldwide. While scientific advances have undoubtedly strengthened our ability to respond to and mitigate the mortality of infectious disease threats, events over the past two decades have illustrated our continued vulnerability to economic consequences from these threats. To assess the current understanding of the interaction of infectious disease threats with economic activity and suggest potential new areas of research, the National Academies of Sciences, Engineering, and Medicine planned a 1.5-day public workshop on understanding the economics of microbial threats. This workshop built on prior work of the Forum on Microbial Threats and aimed to help transform current knowledge into immediate action. This publication summarizes the presentations and discussions from the workshop.

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

The evaluation of reproductive, maternal, newborn, and child health (RMNCH) by the Disease Control Priorities, Third Edition (DCP3) focuses on maternal conditions, childhood illness, and malnutrition. Specifically, the chapters address acute illness and undernutrition in children, principally under age 5. It also covers maternal mortality, morbidity, stillbirth, and influences to pregnancy and pre-pregnancy. Volume 3 focuses on developments since the publication of DCP2 and will also include the transition to older childhood, in particular, the overlap and commonality with the child development volume.The DCP3 evaluation of these conditions produced three key findings:1. There is significant difficulty in measuring the burden of key conditions such as unintended pregnancy, unsafe abortion, nonsexually transmitted infections, infertility, and violence against women.2. Investments in the continuum of care can have significant returns for improved and equitable access, health, poverty, and health systems.3. There is a large difference in how RMNCH conditions affect different income groups; investments in RMNCH can lessen the disparity in terms of both health and financial risk.

Most people know Roald Dahl as a famous write of children's books and adult short stories, but few are aware of his fascination with medicine. Right from his earliest days to the end of his life, Dahl was intrigued by what doctors do, and why they do it. During his lifetime, he and his family suffered some terrible medical tragedies: Dahl nearly died when his fighter plane went down in World War II; his son had severe brain injury in an accident; and his daughter died of measles infection of the brain. But he also had some medical triumphs: he dragged himself back to health after the plane crash, despite a skull fracture, back injuries, and blindness; he was responsible for inventing a medical device (the Wade-Dahl-Till valve) to treat his son's hydrocephalus (water on the brain), and he taught his first wife Patricia to talk again after a devastating stroke. His medical interactions clearly influenced some of his writing – for example the explosive potions in George's Marvellous Medicine. And sometimes his writing impacted on events in his life – for example the research on neuroanatomy he did for his short story William and Mary later helped him design the valve for treating hydrocephalus. In this unique book, Professor Tom Solomon, who looked after Dahl towards the end of his life, examines Dahl's fascination with medicine. Taking examples from Dahl's life, and illustrated with excerpts from his writing, the book uses Dahl's medical interactions as a starting point to explore some extraordinary areas of medical science. Solomon is an award-winning science communicator, and he effortlessly explains the medical concepts underpinning the stories, in language that everyone can understand. The book is also peppered with anecdotes from Dahl's late night hospital discussions with Solomon, which give new insights into this remarkable man's thinking as his life came to an end.

Tobacco use by adolescents and young adults poses serious concerns. Nearly all adults who have ever smoked daily first tried a cigarette before 26 years of age. Current cigarette use among adults is highest among persons aged 21 to 25 years. The parts of the brain most responsible for cognitive and psychosocial maturity continue to develop and change through young adulthood, and adolescent brains are uniquely vulnerable to the effects of nicotine. At the request of the U.S. Food and Drug Administration, Public Health Implications of Raising the Minimum Age of Legal Access to Tobacco Products considers the likely public health impact of raising the minimum age for purchasing tobacco products. The report reviews the existing literature on tobacco use patterns, developmental biology and psychology, health effects of tobacco use, and the current landscape regarding youth access laws, including minimum age laws and their enforcement. Based on this literature, the report makes conclusions about the likely effect of raising the minimum age to 19, 21, and 25 years on tobacco use initiation. The report also quantifies the accompanying public health outcomes based on findings from two tobacco use simulation models. According to the report, raising the minimum age of legal access to tobacco products, particularly to ages 21 and 25, will lead to substantial reductions in tobacco use, improve the health of Americans across the lifespan, and save lives. Public Health Implications of Raising the Minimum Age of Legal Access to Tobacco Products will be a valuable reference for federal policy makers and state and local health departments and legislators.

Volume 41 of'Progress in Orug Research'contains eight reviews and the various indexes which facilitate its use and establish the con­ nection with the previous volumes. The articles in this volume deal with teratogenesis; nephrotoxicity; bacterial resistance to P. lactam antibiotics; eradication of diseases by vaccination; chirality and drug design; endogenous digitalis-like factors; erythropoietin; and sero­ tonin (5HT)-antagonists. 3 All these articles give an excellent overview of the respective fields of research. In the 33 years that POR has existed, the Editor has enjoyed the valu­ able help and advice of many colleagues. Readers, the authors of the reviews, and last but not least, the reviewers have all contributed greatly to the success of this series. Although the comments received so far have generally been favorable, it is nevertheless necessary to analyze and to reassess the current position and the future direction of such a review series. So far, it has been the Editors intention to help disseminate informa­ tion on the vast domain of drug research, and to provide the reader with a tool with which to keep abreast of the latest developments and trends. The reviews in POR are useful to the non-specialists, who can obtain an overview of a particular field of research in a relatively short time. The specialist readers of POR will appreciate the reviews'comprehensive bibliographies, and, in addition, they may even get fresh impulses for their own research.

In 1900, for every 1,000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The National Childhood Vaccine Injury Act, passed in 1986, was intended to bolster vaccine research and development through the federal coordination of vaccine initiatives and to provide relief to vaccine manufacturers facing financial burdens. The legislation also intended to address concerns about the safety of vaccines by instituting a compensation program, setting up a passive surveillance system for vaccine adverse events, and by providing information to consumers. A key component of the legislation required the U.S. Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse events, especially in children. Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health events associated with specific vaccines covered by the National Vaccine Injury Compensation Program (VICP), including the varicella zoster vaccine, influenza vaccines, the hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews peer-reviewed primary studies, summarizes their findings, and evaluates the epidemiological, clinical, and biological evidence. It finds that while no vaccine is 100 percent safe, very few adverse events are shown to be caused by vaccines. In addition, the evidence shows that vaccines do not cause several conditions. For example, the MMR vaccine is not associated with autism or childhood diabetes. Also, the DTaP vaccine is not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma. Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the VICP, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors.

Climate change is occurring, is caused largely by human activities, and poses significant risks for—and in many cases is already affecting—a broad range of human and natural systems. The compelling case for these conclusions is provided in Advancing the Science of Climate Change, part of a congressionally requested suite of studies known as America's Climate Choices. While noting that there is always more to learn and that the scientific process is never closed, the book shows that hypotheses about climate change are supported by multiple lines of evidence and have stood firm in the face of serious debate and careful evaluation of alternative explanations. As decision makers respond to these risks, the nation's scientific enterprise can contribute through research that improves understanding of the causes and consequences of climate change and also is useful to decision makers at the local, regional, national, and international levels. The book identifies decisions being made in 12 sectors, ranging from agriculture to transportation, to identify decisions being made in response to climate change. Advancing the Science of Climate Change calls for a single federal entity or program to coordinate a national, multidisciplinary research effort aimed at improving both understanding and responses to climate change. Seven cross-cutting research themes are identified to support this scientific enterprise. In addition, leaders of federal climate research should redouble efforts to deploy a comprehensive climate observing system, improve climate models and other analytical tools, invest in human capital, and improve linkages between research and decisions by forming partnerships with action-oriented programs.

A single reference source for those working to identify infectious disease agents. Serves as a resource for clinicians, public health professionals, epidemiologists, and clinical microbiologists

Vaccines have saved more lives than any other single medical advance. Yet today only four companies make vaccines, and there is a growing crisis in vaccine availability. Why has this happened? This remarkable book recounts for the first time a devastating episode in 1955 at Cutter Laboratories in Berkeley, California, thathas led many pharmaceutical companies to abandon vaccine manufacture.Drawing on interviews with public health officials, pharmaceutical company executives, attorneys, Cutter employees, and victims of the vaccine, as well as on previously unavailable archives, Dr. Paul Offit offers a full account of the Cutter disaster. He describes the nation's relief when the polio vaccine was developed by Jonas Salk in 1955, the production of the vaccine at industrial facilities such as the one operated by Cutter, and the tragedy that occurred when 200,000 people were inadvertently injected with live virulent polio virus: 70,000 became ill, 200 were permanently paralyzed, and 10 died. Dr. Offit also explores how, as a consequence of the tragedy, one jury's verdict set in motion events that eventually suppressed the production of vaccines already licensed and deterred the development of new vaccines that hold the promise of preventing other fatal diseases.